Treatment of Gastrointestinal Stromal Tumor: Focus on Imatinib Mesylate

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2008 Aug 30

PMID 18728705

Citations 28

Authors

Omar S Din

Penella J Woll

Affiliations

Soon will be listed here.

Abstract

Gastrointestinal stromal tumor (GIST) is a rare primary neoplasm of the gastrointestinal tract, mesentery, or omentum. In the past, surgery has been the only effective treatment. The diagnosis and treatment of GIST has been revolutionized over the past decade, since expression of the receptor tyrosine kinase KIT was shown to occur on these tumors. Mutations in this proto-oncogene commonly cause constitutive activation of the KIT tyrosine kinase receptor, an important factor in the pathogenesis of the disease. The development of specific tyrosine kinase inhibitors, such as imatinib mesylate, has led to a breakthrough in the treatment of advanced GIST. Treatment with this drug has led to significant improvements in survival, with overall response rates in excess of 80%. Side effects are common, but usually manageable. The success of this drug has led to further trials investigating its use in the pre- and postoperative situation. This review summarizes the current knowledge of GIST and imatinib treatment and possible future developments.

Citing Articles

c-Kit Receptors as a Therapeutic Target in Cancer: Current Insights.

Abdellateif M, Bayoumi A, Mohammed M Onco Targets Ther. 2023; 16:785-799.

PMID: 37790582 PMC: 10544070. DOI: 10.2147/OTT.S404648.

Advances in Drug Therapy for Gastrointestinal Stromal Tumour.

Liu J, Li J, Zhu Y, Jing R, Ding S, Zhang J Curr Med Chem. 2023; 31(21):3057-3073.

PMID: 37151058 DOI: 10.2174/0929867330666230505163151.

Imaging Properties and Tumor Targeting of Ga-NeoBOMB1, a Gastrin-Releasing Peptide Receptor Antagonist, in GIST Patients.

Gruber L, Decristoforo C, Uprimny C, Hohenberger P, Schoenberg S, Orlandi F Biomedicines. 2022; 10(11).

PMID: 36428467 PMC: 9687401. DOI: 10.3390/biomedicines10112899.

Laparoscopic subtotal gastrectomy in case of large subcardial GISTs.

Cimpean S, Francois F, Muresan M J Surg Case Rep. 2022; 2022(8):rjac396.

PMID: 36051006 PMC: 9427202. DOI: 10.1093/jscr/rjac396.

Ileal Gastrointestinal Stromal Tumor as a Rare Cause of Gastrointestinal Bleed: A Case Report and Brief Review of the Literature.

Khan A Cureus. 2022; 14(3):e22856.

PMID: 35392443 PMC: 8977124. DOI: 10.7759/cureus.22856.

References

Loughrey M, Mitchell C, Mann G, Michael M, Waring P . Gastrointestinal stromal tumour treated with neoadjuvant imatinib. J Clin Pathol. 2005; 58(7):779-81. PMC: 1770717. DOI: 10.1136/jcp.2004.023226. View

Bauer S, Hartmann J, de Wit M, Lang H, Grabellus F, Antoch G . Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer. 2005; 117(2):316-25. DOI: 10.1002/ijc.21164. View

Mazur M, Clark H . Gastric stromal tumors. Reappraisal of histogenesis. Am J Surg Pathol. 1983; 7(6):507-19. DOI: 10.1097/00000478-198309000-00001. View

Blay J, Bonvalot S, Casali P, Choi H, Debiec-Richter M, Dei Tos A . Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann Oncol. 2005; 16(4):566-78. DOI: 10.1093/annonc/mdi127. View

Joensuu H . Sunitinib for imatinib-resistant GIST. Lancet. 2006; 368(9544):1303-4. DOI: 10.1016/S0140-6736(06)69489-0. View

Burger H, den Bakker M, Kros J, van Tol H, de Bruin A, Oosterhuis W . Activating mutations in c-KIT and PDGFRalpha are exclusively found in gastrointestinal stromal tumors and not in other tumors overexpressing these imatinib mesylate target genes. Cancer Biol Ther. 2005; 4(11):1270-4. DOI: 10.4161/cbt.4.11.2253. View

Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S . Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science. 1998; 279(5350):577-80. DOI: 10.1126/science.279.5350.577. View

Sakakura C, Hagiwara A, Soga K, Miyagawa K, Nakashima S, Yoshikawa T . Long-term survival of a case with multiple liver metastases from duodenal gastrointestinal stromal tumor drastically reduced by the treatment with imatinib and hepatectomy. World J Gastroenterol. 2006; 12(17):2793-7. PMC: 4130995. DOI: 10.3748/wjg.v12.i17.2793. View

Verweij J, Casali P, Zalcberg J, Lecesne A, Reichardt P, Blay J . Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet. 2004; 364(9440):1127-34. DOI: 10.1016/S0140-6736(04)17098-0. View

10.

Ernst S, Hubbs A, Przygodzki R, Emory T, Sobin L, OLeary T . KIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest. 1999; 78(12):1633-6. View

11.

Ryu M, Lee J, Chang H, Kim T, Kang H, Sohn H . Patterns of progression in gastrointestinal stromal tumor treated with imatinib mesylate. Jpn J Clin Oncol. 2006; 36(1):17-24. DOI: 10.1093/jjco/hyi212. View

12.

Mavligit G, Zukwiski A, Ellis L, Chuang V, Wallace S . Gastrointestinal leiomyosarcoma metastatic to the liver. Durable tumor regression by hepatic chemoembolization infusion with cisplatin and vinblastine. Cancer. 1995; 75(8):2083-8. DOI: 10.1002/1097-0142(19950415)75:8<2083::aid-cncr2820750809>3.0.co;2-h. View

13.

Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T . Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res. 1999; 59(17):4297-300. View

14.

Sihto H, Sarlomo-Rikala M, Tynninen O, Tanner M, Andersson L, Franssila K . KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors. J Clin Oncol. 2004; 23(1):49-57. DOI: 10.1200/JCO.2005.02.093. View

15.

Carroll M, Tamura S, Buchdunger E, Zimmermann J, Lydon N, Gilliland D . CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood. 1998; 90(12):4947-52. View

16.

Ishida T, Wada I, Horiuchi H, Oka T, Machinami R . Multiple small intestinal stromal tumors with skeinoid fibers in association with neurofibromatosis 1 (von Recklinghausen's disease). Pathol Int. 1996; 46(9):689-95. DOI: 10.1111/j.1440-1827.1996.tb03673.x. View

17.

Bertucci F, Goncalves A, Monges G, Madroszyk A, Guiramand J, Moutardier V . Acquired resistance to imatinib and secondary KIT exon 13 mutation in gastrointestinal stromal tumour. Oncol Rep. 2006; 16(1):97-101. View

18.

Verweij J, van Oosterom A, Blay J, Judson I, Rodenhuis S, van der Graaf W . Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone.... Eur J Cancer. 2003; 39(14):2006-11. View

19.

Debiec-Rychter M, Sciot R, Cesne A, Schlemmer M, Hohenberger P, van Oosterom A . KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer. 2006; 42(8):1093-103. DOI: 10.1016/j.ejca.2006.01.030. View

20.

Chen H, Pruitt A, Nicol T, Gorgulu S, Choti M . Complete hepatic resection of metastases from leiomyosarcoma prolongs survival. J Gastrointest Surg. 1998; 2(2):151-5. DOI: 10.1016/s1091-255x(98)80006-1. View